MRI-first pathway before initial prostate biopsy, with targeted biopsy only for visible lesions,
does it really help with Avoided biopsy without materially reducing detection of clinically significant cancer?
research showsGrade C. PRECISE detected clinically significant cancer in 79/227 (35%) with the MRI pathway versus 67/225 (30%) with standard biopsy, an absolute difference of +5 points. The one-sided 97.5% CI lower bound of -3.4 points stayed above the prespecified -5-point noninferiority margin. Among 221 men who actually underwent MRI, 83 (37%) had a negative scan and avoided biopsy.
ads claimFinding more lesions or more cancers is not the same as helping people live longer. For the same reason, [verdict 2843 is C with 50 points](/verdicts/gut/real-time-ai-cade-colonoscopy-adenoma-detection/) for AI-assisted adenoma detection during colonoscopy.
Useful facts when choosing a product
- Biopsy was omitted after negative MRI and targeted only when MRI showed a lesion.
- Funding came from the Ontario Institute for Cancer Research and Prostate Cancer Canada, with presentations noting Movember Foundation resources.
- The paper did not report free equipment, product donation, or analysis by a device manufacturer.
What the research actually shows
PRECISE was an open-label phase 3 noninferiority trial at five Canadian academic centers, randomizing 453 men to standard TRUS biopsy (226) or the MRI pathway (227). The primary endpoint was GG2-or-higher cancer detection, with a -5-point margin. At least one adverse event occurred in 145/226 (64%) versus 89/227 (40%), and grade 3 or higher events in 10 (4.4%) versus 8 (3.5%). Hematuria was 48% versus 19%, hematospermia 42% versus 22%, pain 32% versus 15%, and prostatitis 4% versus <1%, but the paper did not assign confirmatory multiplicity-adjusted P values to these comparisons.
Why this is classified as C (56)
Public funding, independent replication, and meeting a prespecified noninferiority margin are strengths, but a detection surrogate and noninferiority design give C with 56 points.
Counterpoint. Biopsy avoidance was established; long-term cancer mortality and the optimal biopsy components after positive MRI remain separate questions.
Rejudgment record. Cross-check applied — Preserved significant-cancer detection and biopsy avoidance in independently replicated publicly funded trials, limited by a detection surrogate and noninferiority design
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R2 | Independently replicated across trials |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | E+ | Meets the clinically important threshold |
The scoring table and the verdict agree (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Noninferior significant-cancer detection with biopsy avoidance | C | The -5-point margin was met and 37% of MRI recipients avoided biopsy. |
| Equivalent long-term prostate-cancer mortality | ? | This was not a trial endpoint. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | Multicenter open-label phase 3 randomized noninferiority trial | 227 | Nonprofit funding from the Ontario Institute for Cancer Research and Prostate Cancer Canada | Proportion diagnosed with GG2-or-higher cancer | 79/227 (35%) vs 67/225 (30%), difference +5 points, one-sided 97.5% CI -3.4 points to infinity; met -5-point margin | Pivotal Canadian trial |
| Study 2 | European multicenter randomized noninferiority trial | 500 | European public and nonprofit funding reported in the PRECISION paper | Clinically significant cancer detection and biopsy avoidance | Twenty-eight percent avoided biopsy, with significant-cancer detection in the same direction | Independent replication |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-08-26).
Final verification and publication gate: Codex · Verification cutoff: 2026-08-26 · Corrections: none
Cite this verdict
[Chamgap] Benefit of an MRI-First Targeted-Biopsy Pathway for Significant-Cancer Detection and Biopsy Avoidance — Evidence Grade C·56. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/mens/mri-first-targeted-biopsy-prostate-cancer-detection/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.